Quantbot Technologies LP Reduces Stock Position in Option Care Health, Inc. $OPCH

Key Points

• Quantbot Technologies LP has reduced its stock position in Option Care Health, Inc. by 27.1%, selling 28,091 shares to end up with a total of 75,530 shares worth approximately $2.64 million.
• Institutional investors hold 98.05% of Option Care Health's stock, with notable increases in holdings observed from firms such as Dimensional Fund Advisors and Allspring Global Investments.
• Recent analyst activity has been positive, with multiple firms raising their target price for Option Care Health, resulting in a consensus "Moderate Buy" rating and a price target of $35.75.

Quantbot Technologies LP cut its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 27.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 75,530 shares of the company's stock after selling 28,091 shares during the quarter. Quantbot Technologies LP's holdings in Option Care Health were worth $2,640,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in OPCH. Brooklyn Investment Group increased its stake in shares of Option Care Health by 186.6% in the 1st quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock worth $42,000 after acquiring an additional 780 shares in the last quarter. Public Employees Retirement System of Ohio increased its stake in shares of Option Care Health by 21.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock worth $43,000 after acquiring an additional 332 shares in the last quarter. Johnson Financial Group Inc. bought a new position in shares of Option Care Health in the 4th quarter worth about $47,000. Bessemer Group Inc. increased its stake in shares of Option Care Health by 62.3% in the 1st quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock worth $54,000 after acquiring an additional 599 shares in the last quarter. Finally, Wealthquest Corp bought a new position in shares of Option Care Health in the 1st quarter worth about $66,000. 98.05% of the stock is currently owned by institutional investors.

Option Care Health Stock Down 0.2%

OPCH stock traded down $0.05 during trading on Tuesday, hitting $28.01. 302,589 shares of the stock traded hands, compared to its average volume of 1,851,914. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $35.53. The firm's 50 day moving average is $29.85 and its two-hundred day moving average is $31.74. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 1.75 and a beta of 0.79. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.00.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the prior year, the firm posted $0.30 EPS. Option Care Health's revenue for the quarter was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. On average, sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on OPCH. UBS Group upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and increased their price target for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Barrington Research reiterated an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research note on Thursday, July 10th. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a research note on Thursday, July 31st. Finally, JMP Securities increased their price target on shares of Option Care Health from $36.00 to $38.00 and gave the stock a "market outperform" rating in a research note on Thursday, July 31st. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.75.

Insider Transactions at Option Care Health

In related news, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were purchased at an average price of $27.51 per share, with a total value of $550,200.00. Following the acquisition, the director directly owned 49,229 shares in the company, valued at $1,354,289.79. The trade was a 68.43% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were bought at an average cost of $27.15 per share, for a total transaction of $977,400.00. Following the acquisition, the director owned 375,390 shares in the company, valued at approximately $10,191,838.50. The trade was a 10.61% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.64% of the company's stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.